UOC
RXDX

UBS O'Connor’s Prometheus Biosciences, Inc. Common Stock RXDX Stock Holding History

UBS O'Connor’s Portfolio RXDX Stock Details RXDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-4,500
Closed -$495K – 784
2022
Q4 		$495K Buy
+4,500
New +$292K 0.01% 619
2022
Q3 		– Sell
-24,000
Closed -$678K – 1031
2022
Q2 		$678K Buy
+24,000
New +$696K 0.01% 797

Other funds holding RXDX

RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
7IH
72 Investment Holdings Stamford, Connecticut $50M AUM 647.58% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.95B AUM 773.9% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
FAM
Fred Alger Management New York $30B AUM 76.99% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

UBS O'Connor's RXDX Position: Q1 2023 in Review

UBS O'Connor sold out of Prometheus Biosciences, Inc. Common Stock (RXDX) in Q1 2023, closing a stake of 4,500 shares — an estimated $495K sold.

UBS O'Connor first reported a position in RXDX in Q2 2022 and held it in 2 quarters. The position peaked at $678K in Q2 2022. 219 funds tracked by Wall St. Rank hold RXDX as of Q1 2023.

  • UBS O'Connor reported no remaining Prometheus Biosciences, Inc. Common Stock position as of Q1 2023 after selling out during the quarter.
  • UBS O'Connor sold 4,500 Prometheus Biosciences, Inc. Common Stock shares in Q1 2023, an estimated $495K.
  • UBS O'Connor first reported a position in Prometheus Biosciences, Inc. Common Stock in Q2 2022 and held it in 2 quarters.
  • UBS O'Connor's Prometheus Biosciences, Inc. Common Stock position peaked at $678K in Q2 2022.
  • 219 funds tracked by Wall St. Rank held Prometheus Biosciences, Inc. Common Stock as of Q1 2023.

Based on UBS O'Connor's 13F filing for Q1 2023, filed 15 May 2023.